OS Therapies Inc
OST-HER2
osteosarcoma
Date
TBD
Advisory committee · Date TBD estimated
What's at stake
An FDA advisory committee reviews OST-HER2 for osteosarcoma around Date TBD. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 8-K
verified 13h ago
“Upcoming U.S. FDA and U.K MHRA meetings scheduled in 2nd quarter of 2026.”